于健，北京航空航天大学医学科学与工程学院教授，硕士/博士生导师。清华大学理学博士，加州大学圣迭戈分校博士后/项目研究员。BMC Cancer 杂志副主编，Med Nov Technol Devices 杂志编委。主持多项国家及省部级科研基金。以第一或通讯作者在 J Clin Invest，Clin Cancer Res，Leukemia，Proc Natl Acad Sci USA 和 Pharmacol Res 等国际权威期刊上发表 SCI 论文 30 余篇，累计引用 2000 余次。参与撰写中/英文著作各 1 部。获 2 项授权美国发明专利，1 项授权中国发明专利。发明的抗体药物已获 FDA 批准进入临床试验，用于治疗复发/难治性 B 细胞恶性肿瘤。
秉承医工交叉的核心理念，将临床资源与高通量多组学技术深度融合，致力于以靶向/免疫治疗为重心的肿瘤应用基础研究，推动新药研发及老药新用和联合用药策略开发, 促进临床治疗方案的优化。
主要研究领域包括但不限于：
1. 多组学：借助单细胞基因组学/单细胞转录组学/蛋白质组学，深入理解肿瘤的异质性和复杂性。
2. 肿瘤生物学：揭示肿瘤对靶向/免疫治疗的耐药机制，为设计更有效的治疗策略提供科学依据。
1. Liu Z, Wu C, Yao Z, Wang Y, Yu Z, Yu J. Targeting lipid metabolism overcomes BTK inhibitor resistance in diffuse large B-cell lymphoma. Med Nov Technol Devices. 2024;22:100295.（中国科技期刊卓越行动计划高起点新刊）
2. Chen W, Shi H, Liu Z, Yang F, Liu J, Zhang L, Wu Y, Xia Y, Ou Y, Li R, Zhang T, Zhang J, Ke X, Hu K, Yu J. Single-Cell Transcriptomics Reveals Immune Reconstitution in Patients with R/R T-ALL/LBL Treated with Donor-Derived CD7 CAR-T Therapy. Clin Cancer Res. 2023, 29(8):1484-1495.（IF = 13.801）
3. Liu J, Liu Z, Zhang J, Chen X, Chen J, Sui L, Yu J. Ibrutinib Inhibits Angiogenesis and Tumorigenesis in a BTK-Independent Manner. Pharmaceutics 2022, 14(9):1876.（IF = 6.525）
4. Liu J, Zhang F, Yu J#, Zhao Q#. Programmed death-ligand 1 expression on CD22-specific chimeric antigen receptor-modified T cells weakens antitumor potential. MedComm 2022, 3(2):e140.（IF = 9.90）
5. Liu Z, Liu J, Zhang T, Li L, Zhang S, Jia H, Xia Y, Shi M, Zhang J, Yue S, Chen X, Yu J. Distinct BTK inhibitors differentially induce apoptosis but similarly suppress chemotaxis and lipid accumulation in mantle cell lymphoma. BMC Cancer 2021, 21(1):732.（IF = 4.638）
6. Zhang D, Guo Y, Zhao Y, Yu L, Chang Z, Pei H, Huang J, Chen C, Xue H, Xu X, Pan Y, Li N, Zhu C, Zhao ZJ, Yu J#, Chen Y#. Expression of a recombinant FLT3 ligand and its emtansine conjugate as a therapeutic candidate against acute myeloid leukemia cells with FLT3 expression. Microb Cell Fact. 2021, 20(1): 67.（IF = 6.352）
7. Liu J, Yan W, Liu Z, Han Y, Xia Y, Yu J. A colloidal gold-based immunochromatographic strip for rapid detection of SARS-CoV-2 antibodies after vaccination. Med Nov Technol Devices. 2021;11:100084.（中国科技期刊卓越行动计划高起点新刊）
8. Liu Z, Liu J, Zhang T, Shi M, Chen X, Chen Y, Yu J. Destabilization of ROR1 enhances activity of Ibrutinib against chronic lymphocytic leukemia in vivo. Pharmacol Res. 2020; 151:104512.（IF = 10.334）
9. Yu J, Chen L, Cui B, Wu C, Choi MY, Chen Y, et al. Cirmtuzumab inhibits Wnt5a-induced Rac1 activation in chronic lymphocytic leukemia treated with ibrutinib. Leukemia. 2017;31(6):1333-1339.（IF = 12.883）
10. Yu J, Chen L, Chen Y, Hasan MK, Ghia EM, Zhang L, et al. Wnt5a induces ROR1 to associate with 14-3-3zeta for enhanced chemotaxis and proliferation of chronic lymphocytic leukemia cells. Leukemia. 2017;31(12),2608-2614.（IF = 12.883）
11. Yu J, Chen L, Cui B, Widhopf GF, 2nd, Shen Z, Wu R, et al. Wnt5a induces ROR1/ROR2 heterooligomerization to enhance leukemia chemotaxis and proliferation. J Clin Invest. 2016;126(2):585-598.（IF = 19.456）
12. Lu D#, Choi MY#, Yu J#, Castro JE, Kipps TJ, Carson DA. Salinomycin inhibits Wnt signaling and selectively induces apoptosis in chronic lymphocytic leukemia cells. Proc Natl Acad Sci U S A. 2011;108(32):13253-13257.（IF = 9.58）
1. 于健，刘佳，刘卓君；依鲁替尼作为血管抑制剂的作用、降低其副作用的药物及其用途；专利号：ZL202010668072.9；授权日：2022.06.24.
2. Thomas James Kipps, Jian Yu, Bing Cui, Liguang Chen, George Widhopf and Charles Prussak; Antibodies and vaccines for use in treating ROR1 cancers and inhibiting metastasis; International Publication Number: WO 2014/031174 A1; International Publication Date: Feb 27, 2014.
3. 袁中一，于健，李东阳，杨晟；高效表达D-氨基酸氧化酶的甲醇酵母，其构建及发酵方法；专利号：ZL01132380.9；授权日：2004.03.10.